Prevalence and predictors of female sexual dysfunction among sexually active women in the diabetes prevention program outcomes study

Authors

Priyanka Gupta, Department of Urology, University of Michigan, Ann Arbor, Michigan, USA.
Lindsay Doherty, Department of Biostatistics and Bioinformatics, Biostatistics Center, Milken Institute School of Public Health, George Washington University, Washington, District of Columbia, USA.
Marinella Temprosa, Department of Biostatistics and Bioinformatics, Biostatistics Center, Milken Institute School of Public Health, George Washington University, Washington, District of Columbia, USA.
Rodica Pop-Busui, Division of Metabolism, Endocrinology and Diabetes, Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan, USA.
Kishore M. Gadde, Department of Surgery, University of California Irvine, Orange, California, USA.
Prachi Singh, Pennington Biomedical Research Center, Louisiana State University System, Baton Rouge, Louisiana, USA.
Arthur H. Owora, Department of Epidemiology and Biostatistics, Indiana University School of Public Health, Bloomington, Indiana, USA.
Hunter Wessells, Department of Urology and Diabetes, Research Center, University of Washington School of Medicine, Seattle, Washington, USA.
Aruna V. Sarma, Department of Urology, University of Michigan, Ann Arbor, Michigan, USA.

Document Type

Journal Article

Publication Date

4-1-2024

Journal

Neurourology and urodynamics

Volume

43

Issue

4

DOI

10.1002/nau.25436

Keywords

diabetes; female sexual dysfunction; sexual health

Abstract

OBJECTIVE: To determine the burden and identify correlates of female sexual dysfunction (FSD) among women with prediabetes (PreD) and type 2 diabetes (T2D) enrolled in the Diabetes Prevention Program (DPP) Outcomes Study (DPPOS). METHODS: The DPPOS visit included the Female Sexual Function Index (FSFI) to determine sexual function. Of 1464 participants, 1320 (90%) completed the (FSFI) and 426 were sexually active. A backward selection multivariable logistic regression model estimated the odds of FSD for sociodemographic, clinical, and diabetes-related covariates. RESULTS: One hundred and eighty-five (43%) had a score of ≤26.55 and met the criteria for FSD. After adjustment for DPP treatment and age, urinary incontinence (UI) (odds ratio [OR] = 1.91, 95% confidence interval [CI] = 1.15-3.17) and hysterectomy (OR = 1.89, 95% CI = 1.01-3.53) were associated with increased odds of FSD. Increased body mass index was protective for FSD (OR = 0.93 per kg/m, 95% CI = 0.89-0.96). Michigan Neuropathy Screening Instrument-based peripheral neuropathy (mean±SD scores 1.1±1.3 vs. 0.9±1.1, p < 0.0001) and Electrocardiogram (ECG)-based autonomic dysfunction measures (mean ± SD heart rate levels 64.3 ± 6.8 vs. 65.6 ± 10.2, p = 0.008) were associated with FSD. There were no differences in diabetes rates between women who did (66.5%) and did not (66%) have (p = 0.7). CONCLUSIONS: FSD is prevalent in women with PreD and T2D. Our findings suggest that FSD is associated with neuropathic complications commonly observed in PreD and T2D.

APA Citation

Gupta, Priyanka; Doherty, Lindsay; Temprosa, Marinella; Pop-Busui, Rodica; Gadde, Kishore M.; Singh, Prachi; Owora, Arthur H.; Wessells, Hunter; and Sarma, Aruna V., "Prevalence and predictors of female sexual dysfunction among sexually active women in the diabetes prevention program outcomes study" (2024). GW Authored Works. Paper 4800.
https://hsrc.himmelfarb.gwu.edu/gwhpubs/4800

Department

Biostatistics and Bioinformatics